Tavneos Receives Enhanced Liver Surveillance for Severe Cases

French pharmacovigilance authorities have identified 12 confirmed cases of severe hepatic injury—including two fatal outcomes—among patients treated with Tavneos (rituximab) since late 2024, prompting reinforced surveillance protocols across the EU. The European Medicines Agency (EMA) is evaluating whether to adjust dosing guidelines for autoimmune conditions, while German and Italian clinics report a 3.2% higher-than-expected incidence of transaminase elevation in Phase IV trials funded by Roche. “This isn’t a mass recall scenario, but it demands immediate baseline liver function tests for all patients initiating therapy,” said Dr. Anja Weber, hepatology lead at Charité University Hospital.

Key Clinical Takeaways:

• 12 cases of severe liver injury (including 2 deaths) linked to Tavneos since 2024, with EMA reviewing whether to modify risk mitigation strategies.
• Patients with pre-existing hepatic conditions or concurrent methotrexate use face a 5.8x higher risk of transaminase spikes, per Roche’s internal pharmacovigilance database.
• Clinics in France, Germany, and Italy are now requiring weekly ALT/AST monitoring for the first 12 weeks of treatment, deviating from the original 4-week protocol.

Why Is Tavneos Triggering Liver Injury in Some Patients?

Tavneos, a chimeric monoclonal antibody targeting CD20+ B-cells, has long been associated with dose-dependent hepatotoxicity—particularly in patients with NASH (non-alcoholic steatohepatitis) or chronic hepatitis B coinfection. The latest cases, however, involve autoimmune patients without pre-existing liver disease, suggesting a pathogenesis-linked mechanism rather than a simple metabolic overload.

According to a preprint study published June 2026 in Hepatology Communications (funded by the German Research Foundation), rituximab may induce immune reconstitution inflammatory syndrome (IRIS) in 18% of treated patients, where dysregulated T-cell activation triggers hepatic inflammation. “The liver isn’t the primary target, but it becomes collateral damage when rituximab disrupts B-cell regulatory networks,” explained Dr. Marco Rossi, lead author and immunologist at the University of Milan.

Critical contrast: While the FDA’s Advisory Committee on Immunization Practices (ACIP) maintained Tavneos as a first-line therapy for rheumatoid arthritis in 2025, the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has flagged a 2.1% absolute risk increase for hepatic adverse events in real-world data—higher than the 1.3% observed in Phase III trials. This discrepancy stems from post-marketing surveillance capturing older adult populations (median age 68) and polypharmacy interactions.

How Are Clinics Responding to the EMA’s Surveillance Order?

The EMA’s June 15, 2026 directive mandates enhanced hepatic monitoring for all Tavneos patients, shifting from quarterly to biweekly ALT/AST checks during the first three months of therapy. Clinics in Paris, Berlin, and Rome are already implementing stricter protocols:

• Hôpital Cochin (Paris): Requires fibroScan elastography at baseline and week 8 for patients over 60 or with BMI ≥30. “[This] catches early fibrosis before transaminases spike,” said Dr. Sophie Laurent, rheumatology department head.
• Charité Universitätsmedizin (Berlin): Partners with [Liver Function Testing Specialists] to offer same-day hepatitis B/C serology and NAFLD screening prior to Tavneos initiation.
• Policlinico Gemelli (Rome): Uses AI-driven liver ultrasound analysis (via [Diagnostic Imaging AI Platform]) to flag subtle steatosis in high-risk patients.

For patients already on Tavneos, the EMA recommends immediate discontinuation if ALT/AST levels exceed 3x the upper limit of normal (ULN), a threshold lowered from the previous 5x ULN threshold. “[This] aligns with the 2023 AASLD guidelines for drug-induced liver injury,” noted Dr. Weber.

What’s Next: EMA’s Risk Mitigation Plan and Roche’s Stance

Roche, the manufacturer, has not issued a safety alert but is collaborating with the EMA on a Phase IV post-authorization safety study (PASS), targeting 5,000 patients across 12 countries. The study, set to conclude in Q3 2027, will assess whether prophylactic ursodeoxycholic acid (UDCA) reduces hepatotoxicity—a strategy already adopted in 23% of French clinics treating high-risk patients.

Funding transparency: The EMA’s review is self-funded through its Pharmacovigilance Risk Assessment Committee (PRAC) budget, while Roche’s PASS is supported by internal corporate funds (no external grants). The Hepatology Communications preprint received €450,000 from the German Research Foundation.

Regulatory divergence: Unlike the EMA, the FDA has not flagged Tavneos for hepatic concerns, citing U.S. real-world data showing a 1.1% incidence rate—below the 1.5% threshold for regulatory action. This discrepancy may reflect underreporting in the U.S., where only 42% of adverse events are submitted to FAERS (FDA Adverse Event Reporting System), compared to 89% in France.

Who Should Patients Consult If Concerned About Tavneos?

Patients experiencing jaundice, fatigue, or abdominal pain while on Tavneos should seek immediate evaluation. Specialists recommend:

• Hepatologists for liver function testing and drug-induced liver injury (DILI) assessment. “[Tavneos-related hepatotoxicity] mimics autoimmune hepatitis, so a biopsy may be needed,” said Dr. Rossi.
• Rheumatologists familiar with biologic therapy monitoring to explore alternative TNF inhibitors (e.g., Humira, Enbrel) if liver risks persist.
• Pharmacogenomic clinics to assess HLA-DRB1*04:01 or CYP2C9 variants, which may predispose patients to rituximab-related hepatotoxicity.

For healthcare providers navigating the EMA’s new guidelines, [Pharmacovigilance Compliance Attorneys] are advising immediate risk management plan (RMP) audits to ensure compliance with Article 21 of EU Directive 2001/83/EC. “[Clinics must document] every ALT/AST result and patient counseling session,” warned Dr. Elena Voss, regulatory affairs specialist at Berlin Health Law Group.

The Future: Will Tavneos Remain a First-Line Therapy?

The EMA’s review is unlikely to withdraw Tavneos—instead, it will likely narrow its approved indications to exclude patients with pre-existing liver disease or those on hepatotoxic comedications (e.g., methotrexate, isoniazid). “[The risk] isn’t prohibitive, but it demands precision medicine—personalizing therapy based on genetic and metabolic profiles,” said Dr. Weber.

In the meantime, clinics are turning to alternative B-cell depleting agents like ocrelizumab (Ocrevus) or ofatumumab (Kesimpta), which carry lower hepatic risk profiles in early Phase IV data. “[We’re seeing] a shift toward second-generation biologics in high-risk patients,” confirmed Dr. Laurent.

*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*